Swedish biopharmaceutical company Hansa Biopharma AB (STO:HNSA) announced on Thursday that it has received the 2025 SwedenBIO Award at the SwedenBIO Summit in Stockholm.
This award aims to recognise companies that drive scientific progress, operational excellence, and international impact.
Through its pioneering enzyme technology, Hansa enables life-saving transplantation for highly sensitised patients with previously unmet needs.
Renee Aguiar-Lucander, CEO, Hansa Biopharma said: "I am truly delighted and deeply honoured to receive this award on behalf of everyone at Hansa Biopharma. This recognition reflects the great momentum we've built heading into 2026 -- powered by our strong US Phase 3 data, the upcoming FDA review process, and the anticipated Phase 3 readout from our European Phase 3 trial later this year. Thank you to the SwedenBIO organisation and judges for this recognition. We're proud of how far we've come, and excited for the journey ahead."
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval